Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IDUA | P35475 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14584179 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL29044161 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL2152162 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL19155610 | 0.83 | FUCA1 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL712837 | 0.79 | CYP3A4 (0.39) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL28475631 | 0.78 | LGALS3 (0.33) | IDUA | |
| SCHEMBL2189191 | 0.77 | TSHR (0.45) | TSHR | |
| SCHEMBL2189182 | 0.77 | TSHR (0.45) | TSHR | |
| SCHEMBL28214269 | 0.77 | AHCY (0.34) | IDUA | |
| SCHEMBL14614369 | 0.76 | POLB (0.32) | CYP3A4TSHRPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-10 | — | — | US | disclosed |
| EP-2098533-A1 | Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098534-A1 | Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | GALE, UGGT1, UGT1A3 | CYP3A4 76/4885TSHR 3312/4885POLB 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.